Abstract 1054
Background
Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody (mAb), with functional Fc domain capable of inducing ADCC, that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors. Cosibelimab is being evaluated in a multicenter phase 1 study (NCT03212404) in pts with advanced cancers. We present preliminary safety, efficacy and PK data.
Methods
Pts were ≥18 years old with advanced cancers and adequate organ function. In dose escalation, pts received cosibelimab administered intravenously at sequential fixed doses of 200 mg, 400 mg, or 800 mg every 2 weeks (q2w) or 1200 mg every 3 weeks (q3w) using a 3 + 3 design. Following dose escalation, multiple tumor-specific expansion cohorts are being enrolled at 800 mg q2w to further evaluate safety and efficacy.
Results
As of April 23, 2019, 65 pts (47M/18F, median age 64 years) with diverse tumor types received cosibelimab in dose escalation and expansion cohorts. Cosibelimab has demonstrated acceptable tolerability with no dose‐limiting toxicities. Treatment‐related adverse events (AEs) occurred in 32/65 (49%) pts, most commonly rash (n = 9, 14%) and fatigue (n = 6, 9%). Treatment‐related grade ≥3 AEs occurred in 5/65 (8%) pts, all grade 3, and included anemia, asthenia, hypertension, hyponatremia, and high blood pressure (n = 1 [2%] each). Cosibelimab demonstrated linear PK with features consistent with marketed anti-PD-L1 mAbs. Thirty-six pts were response evaluable of which 10/36 (28%) pts achieved a partial response by RECIST 1.1 criteria (including cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma), 17/36 (47%) pts achieved stable disease, and 24/36 (67%) pts experienced target lesion reductions versus baseline. Forty-two pts remain on treatment (range, 1-17+ mos).
Conclusions
Cosibelimab has demonstrated a safe and well-tolerated safety profile with evidence of durable anti‐tumor activity in several advanced cancers, and linear PK. Cosibelimab is being further evaluated in multiple tumor-specific expansion cohorts. Updated results will be presented.
Clinical trial identification
NCT03212404.
Editorial acknowledgement
Legal entity responsible for the study
Checkpoint Therapeutics, Inc.
Funding
Checkpoint Therapeutics, Inc.
Disclosure
P.R. Clingan: Research grant / Funding (institution): Merck Sharp & Dohme Corp; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Bristol Myers; Research grant / Funding (institution): Checkpoint Therapeutics, Inc. A.M. Mant: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. G.E. Richardson: Research grant / Funding (institution): Novotech; Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Alphapharm; Research grant / Funding (institution): Checkpoint Therapeutics. D.M. Kowalski: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. P. Koralewski: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. I. Lugowska: Research grant / Funding (institution): Checkpoint Therapeutics, Inc.; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol Myers; Honoraria (self): Merck; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self): Amgen; Honoraria (self): Janssen; Honoraria (self), Research grant / Funding (institution): Novartis. A. Dechaphunkul: Speaker Bureau / Expert testimony: Roche; Travel / Accommodation / Expenses: Eisai; Research grant / Funding (institution): Checkpoint Therapeutics. C. Charoentum: Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Checkpoint Therapeutics. A. Sookprasert: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Honoraria (self): Eisai; Research grant / Funding (institution): Checkpoint Therapeutics, Inc. V. Sriuranpong: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self): Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Boehringer; Honoraria (self), Research grant / Funding (institution): Taiho; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Honoraria (self): Bristol Myers; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Checkpoint Therapeutics. A. Akopov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. V. Kozlov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. N. Fadeeva: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. B. Kasparov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. N.V. Kovalenko: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. V. Oschepkov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. L. Gorelik: Shareholder / Stockholder / Stock options, Full / Part-time employment: Checkpoint Therapeutics, Inc. Y. Kunes: Shareholder / Stockholder / Stock options: Checkpoint Therapeutics, Inc. J. Oliviero: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Checkpoint Therapeutics, Inc. D.L. Harris: Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Checkpoint Therapeutics; Research grant / Funding (institution): Targovax.
Resources from the same session
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract